News

Merck Serono bags MS licence option
Enlarge image

BusinessGermany

Merck Serono bags MS licence option

06.02.2013 - Merck Serono has secured an exclusive licence option for Opexa Therapeutics’ autologous T cell-based Multiple Sclerosis therapy imilecleucel-T.

Opexa’s Tcelna (imilecleucel-T) therapy currently is tested in a Phase IIb study on patients with Secondary Progressive MS (SPMS), which is less common than relapsing forms of MS that are targeted by Merck’s blockbuster Rebif® (interferon beta-1a)  In case of market entry and successful commercialisation, the US firm could gain US$225m in total from the option and license agreement.

Under the terms of the contract, Opexa will receive an upfront payment of $5 million for granting an option to Merck Serono for the exclusive license of the Tcelna (imilecleucel-T) programme as a treatment of MS. The option may be exercised prior to, or upon completion of, Opexa’s proof-of-concept trial. If Merck Serono opts for the programme, Opexa is eligible for $25m or $15m upfront depending on fulfilment of certain undisclosed conditions. The Germans, in return, would receive worldwide development and commercial rights in MS, excluding Japan. When exercising the option, Merck Serono would have to pay all clinical development, as well as the cost for regulatory authorisation and marketing of the MS programme. Milestone payments to Opexa could sum up to $195m plus a tiered royalty rate from the high single digits to the mid-teens based on net sales.

Under the agreement, Opexa will have an option right to co-fund development, under which the company would participate in economic support for future clinical development of the programme in exchange for additional royalty consideration. In addition to retaining all rights outside of MS as well as retaining the ability to commercialise imilecleucel-T in Japan, Opexa also retains certain manufacturing rights related to the programme. 

Tcelna (imilecleucel-T) is an autologous T cell therapy. After collection of peripheral blood mononuclear cells, myelin-reactive T-cells (MRTCs) raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP) are expanded, irradiated and given back to the patient subcutaneously to trigger a therapeutic immune response.

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/merck-serono-bags-ms-licence-option.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BASILEA133.60 CHF4.70%
  • WILEX4.20 EUR3.45%
  • STRATEC BIOMEDICAL48.52 EUR3.23%

FLOP

  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%

TOP

  • 4SC4.65 EUR257.7%
  • SYNGENTA422.00 CHF28.3%
  • SARTORIUS169.65 EUR18.6%

FLOP

  • CYTOS0.63 CHF-37.6%
  • MEDIGENE8.58 EUR-33.2%
  • CO.DON2.89 EUR-8.3%

TOP

  • WILEX4.20 EUR418.5%
  • FORMYCON27.70 EUR316.5%
  • 4SC4.65 EUR315.2%

FLOP

  • MOLOGEN4.92 EUR-53.7%
  • BIOFRONTERA2.30 EUR-28.6%
  • PAION2.51 EUR-22.8%

No liability assumed, Date: 25.05.2015